We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
- Authors
Motzer, R J; Rakhit, A; Ginsberg, M; Rittweger, K; Vuky, J; Yu, R; Fettner, S; Hooftman, L
- Abstract
Pegylated (40 kd) interferon alfa-2a (IFNalpha2a) (PEGASYS, Hoffman-La Roche, Nutley, NJ; PEG-IFN) is a modified form of recombinant human IFNalpha2a with sustained absorption and prolonged half-life after subcutaneous administration. A phase I study of PEG-IFN with pharmacokinetic and pharmacodynamic evaluations was conducted in previously untreated patients with advanced renal cell carcinoma (RCC).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Vol 19, Issue 5, p1312
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2001.19.5.1312